Literature DB >> 7871265

[Mycoplasma infection with Stevens-Johnson syndrome and antiphospholipid antibodies: apropos of 2 cases].

B Catteau1, E Delaporte, E Hachulla, F Piette, H Bergoend.   

Abstract

We report two cases of Mycoplasma pneumoniae infections associated with Stevens-Johnson syndrome and antiphospholipid antibodies. Such an association has been noted once in the literature. The relationship between antiphospholipid antibodies and Stevens-Johnson syndrome and others cutaneous manifestations of infections diseases is discussed. Though mainly described in systemic lupus erythematosus and autoimmune diseases, anticardiolipin antibodies and lupus anticoagulant have been found in many infectious disorders. But in the latter conditions, they have been considered by many authors as "non pathogenic" or "non prothrombotic" on epidemiologic and immunologic data. We suggest that antiphospholipid antibodies could possibly play a role in their pathogenesis especially as the mechanisms are not to date clearly understood.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7871265     DOI: 10.1016/0248-8663(96)80659-x

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

Review 1.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

2.  Prevalence of antiphospholipid and antiplatelet antibodies in human immunodeficiency virus (HIV)-infected Chilean patients.

Authors:  Iván Palomo; Marcelo Alarcón; Cecilia Sepulveda; Jaime Pereira; Ricardo Espinola; Silvia Pierangeli
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

3.  Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome.

Authors:  A Yáñez; L Cedillo; O Neyrolles; E Alonso; M C Prévost; J Rojas; H L Watson; A Blanchard; G H Cassell
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.